| Human immunodeficiency virus I infection
Delstrigo vs Odefsey
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Delstrigo vs Odefsey with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOdefsey has a higher rate of injection site reactions vs Delstrigo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Odefsey but not Delstrigo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Delstrigo
Odefsey
At A Glance
Oral
Once daily
NNRTI/NRTI combination
Oral
Once daily
NRTI + NNRTI combination
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection One tablet orally once daily with or without food in adults and pediatric patients weighing at least 35 kg.
With rifabutin co-administration Take one tablet of DELSTRIGO once daily plus one tablet of doravirine 100 mg (PIFELTRO) approximately 12 hours after the DELSTRIGO dose for the duration of rifabutin co-administration.
Human immunodeficiency virus I infection One tablet (emtricitabine 200 mg, rilpivirine 25 mg, tenofovir alafenamide 25 mg) orally once daily with a meal
Contraindications
- Co-administration with strong CYP3A inducers, including carbamazepine, oxcarbazepine, phenobarbital, phenytoin, enzalutamide, rifampin, rifapentine, mitotane, or St. John's wort
- Previous hypersensitivity reaction to lamivudine
- Coadministration with carbamazepine
- Coadministration with oxcarbazepine
- Coadministration with phenobarbital
- Coadministration with phenytoin
- Coadministration with rifampin
- Coadministration with rifapentine
- Coadministration with dexamethasone (more than a single dose)
- Coadministration with St. John's wort
- Coadministration with proton pump inhibitors
Adverse Reactions
Most common (>=5%) Dizziness, nausea, abnormal dreams
Serious Severe acute exacerbation of hepatitis B, new onset or worsening renal impairment, bone loss and mineralization defects, immune reconstitution syndrome
Postmarketing Stevens-Johnson syndrome/toxic epidermal necrolysis, hepatitis, lactic acidosis, hepatic steatosis, rhabdomyolysis, acute renal failure, Fanconi syndrome, anaphylaxis, anemia
Most common (>=2%) Headache, sleep disturbances
Serious Severe acute exacerbations of hepatitis B, skin and hypersensitivity reactions, hepatotoxicity, depressive disorders, new onset or worsening renal impairment, lactic acidosis/severe hepatomegaly with steatosis, immune reconstitution syndrome
Postmarketing Weight increased, severe skin and hypersensitivity reactions including DRESS, nephrotic syndrome, angioedema, urticaria, rash, acute renal failure, acute tubular necrosis, proximal renal tubulopathy, Fanconi syndrome
Pharmacology
DELSTRIGO combines doravirine, an NNRTI that non-competitively inhibits HIV-1 reverse transcriptase; lamivudine, a nucleoside analogue NRTI that terminates HIV-1 DNA chain elongation after phosphorylation to lamivudine triphosphate; and tenofovir disoproxil fumarate, a nucleotide analogue prodrug that, following conversion to tenofovir diphosphate, competitively inhibits HIV-1 reverse transcriptase and causes DNA chain termination.
Odefsey is a fixed-dose combination of emtricitabine (an NRTI that inhibits HIV-1 reverse transcriptase by chain termination), rilpivirine (an NNRTI that non-competitively inhibits HIV-1 reverse transcriptase), and tenofovir alafenamide (a prodrug that is converted to tenofovir, an NRTI inhibiting HIV-1 reverse transcriptase by chain termination).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Delstrigo
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (11/12)
Odefsey
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Delstrigo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Odefsey
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Delstrigo
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Odefsey
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Delstrigo or Pifeltro Savings CouponCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Gilead Advancing Access Patient Assistance Program/Medication Assistance Program (PAP/MAP)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DelstrigoView full Delstrigo profile
OdefseyView full Odefsey profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.